List of Excipients in Branded Drug FAMOTIDINE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Padagis US LLC	FAMOTIDINE	famotidine	0574-0147	CARBOXYMETHYLCELLULOSE SODIUM
Padagis US LLC	FAMOTIDINE	famotidine	0574-0147	CELLULOSE, MICROCRYSTALLINE
Padagis US LLC	FAMOTIDINE	famotidine	0574-0147	CITRIC ACID MONOHYDRATE

Generic Drugs Containing FAMOTIDINE

Company	Ingredient	NDC	Excipient
Teva Pharmaceuticals USA Inc	famotidine	0093-2748	CELLULOSE, MICROCRYSTALLINE
Teva Pharmaceuticals USA Inc	famotidine	0093-2748	FD&C RED NO. 40
Teva Pharmaceuticals USA Inc	famotidine	0093-2748	FD&C YELLOW NO. 6

What are the Most Frequently-Used Excipients in FAMOTIDINE?

# Of NDCs	Excipient
1	ACETIC ACID
1	ALCOHOL
1	ALUMINUM OXIDE

Famotidine Excipient Strategy and Commercial Opportunities

Last updated: August 21, 2026

Famotidine is a mature, low-cost H2-receptor antagonist with limited active-ingredient exclusivity and broad generic competition. Commercial opportunity has shifted from molecule protection to differentiated dosage forms, taste masking, combination products, improved stability, pediatric delivery, rapid onset, and manufacturing efficiency. The strongest excipient strategies target chewable and orally disintegrating products, fixed-dose antacid combinations, liquid formulations, and modified-release systems.

What is the commercial status of famotidine?

Famotidine is marketed as a prescription and over-the-counter drug for short-term treatment and prevention of heartburn, gastroesophageal reflux disease, peptic ulcer disease, and other acid-related disorders. In the United States, branded Pepcid products are associated with Kenvue, while numerous generic products are marketed by companies including Teva, Hikma, Viatris, Dr. Reddy's Laboratories, Rising Pharmaceuticals, and other abbreviated new drug application holders.

Famotidine is available in several dosage forms:

Dosage form	Common strengths or concentrations	Primary commercial use
Immediate-release tablets	10 mg, 20 mg, 40 mg	Prescription and OTC heartburn or acid suppression
Chewable tablets	Commonly 10 mg and combination strengths	OTC rapid-use heartburn products
Oral suspension or powder for suspension	Product-specific	Pediatric and patients with swallowing difficulty
Injection	10 mg/mL and other hospital presentations	Intravenous treatment in hospital settings
Combination chewables	Famotidine with calcium carbonate and magnesium hydroxide	OTC rapid symptom relief plus acid suppression

The U.S. Food and Drug Administration approved Pepcid tablets in 1986 and injection in 1988. Famotidine is now a mature generic active pharmaceutical ingredient with a large installed manufacturing base and relatively low unit economics.[1][2]

When does famotidine lose exclusivity?

Famotidine lost meaningful U.S. active-ingredient and basic product exclusivity many years ago. The original Pepcid active-ingredient patent, U.S. Patent No. 4,283,408, expired in the early 2000s after patent-term adjustments and extensions were exhausted. Current commercial protection generally depends on trademarks, formulation claims, manufacturing know-how, regulatory positioning, and product-specific patents rather than protection for famotidine itself.

What is the Orange Book status of famotidine?

The FDA Orange Book identifies approved prescription products and any relevant patent or exclusivity information submitted by sponsors. For a mature generic product such as famotidine, the commercial landscape is principally driven by abbreviated new drug applications and product-level approval requirements rather than a remaining basic patent estate.

Orange Book exposure can still matter for:

• Prescription famotidine tablets and injections
• New combination products
• New dosage forms
• Method-of-use claims
• Formulation claims submitted with eligible new drug applications
• Regulatory exclusivity linked to a new clinical or delivery innovation

An Orange Book listing does not automatically establish enforceable patent strength. The scope, expiration date, listed claims, and Paragraph IV certification must be reviewed product by product in the current Orange Book and associated FDA records.[3]

Are there current Paragraph IV challenges to famotidine?

Generic famotidine tablets and injections entered the market long ago, so the principal active-ingredient product is not a current Paragraph IV opportunity. Paragraph IV risk is more relevant to later products with new formulations, combinations, or delivery systems.

A company developing a differentiated famotidine product could face:

• Paragraph IV challenges against formulation patents
• Patent litigation involving combination compositions
• Disputes over obviousness of excipient combinations
• Regulatory disputes over whether the product is eligible for an abbreviated pathway
• Trademark or trade-dress disputes involving OTC presentation

For a basic immediate-release tablet using conventional excipients, patent protection is weak. A defensible filing must claim a measurable technical result, such as improved palatability, dissolution under defined conditions, suspension stability, reduced impurity formation, or improved dose uniformity.

Which excipient properties matter most for famotidine?

Famotidine excipient selection is driven by dose uniformity, dissolution, taste, pH control, suspension stability, tablet robustness, and patient usability. The active ingredient is typically administered at a relatively low oral dose, which makes manufacturing uniformity manageable, but the molecule's taste and dosage-form limitations create formulation opportunities.

Solubility and dissolution

Famotidine has pH-dependent aqueous behavior and is a weakly basic compound. Formulators must control microenvironmental pH and wetting to achieve reproducible dissolution. Suitable strategies may include:

• Microcrystalline cellulose for tablet structure
• Crospovidone, croscarmellose sodium, or sodium starch glycolate for disintegration
• Povidone or copovidone for granulation and binding
• Colloidal silicon dioxide for flow
• Magnesium stearate or sodium stearyl fumarate for lubrication
• Surfactants or wetting agents where justified by dissolution data
• Buffering excipients when product pH affects stability or release

The preferred excipient system depends on whether the product is a conventional tablet, chewable, suspension, or rapid-dissolution dosage form. Excessive lubricant can slow wetting and dissolution, especially in directly compressed tablets.

Taste masking

Taste is one of the clearest formulation opportunities. Famotidine products intended to dissolve in the mouth or be chewed require effective masking of bitterness and sulfur-associated taste notes.

Potential approaches include:

• Polymer coating of famotidine particles
• Ion-exchange resin complexes
• Lipid or wax-based microparticles
• Cyclodextrin complexes
• Use of sweeteners, flavors, and cooling agents
• Effervescent systems that shorten oral residence time
• Multiparticulate granules with coated active particles

Taste-masking patents are more defensible when they define coating composition, particle-size distribution, dissolution behavior, sensory thresholds, and stability. A broad claim covering famotidine with a conventional sweetener is likely to face substantial obviousness risk.

Suspension stability

Liquid famotidine products require control of sedimentation, redispersibility, viscosity, microbial protection, and dose uniformity. Excipients may include:

• Suspending agents such as xanthan gum, microcrystalline cellulose with carboxymethylcellulose sodium, or polymers
• Wetting agents
• Buffers
• Sweeteners and flavors
• Preservatives where permitted and necessary
• Chelating agents where metal-catalyzed degradation is a concern

A commercial suspension should maintain uniform concentration after shaking and should deliver an accurate dose through a dosing syringe or cup. The most valuable formulation claims would connect a defined excipient ratio to a measured redispersibility or assay-uniformity result.

What formulations are protected by famotidine patents?

The basic famotidine molecule and conventional immediate-release tablets have limited remaining patent value. Commercially relevant formulation opportunities are more likely to involve:

Formulation platform	Commercial rationale	Patent potential
Taste-masked chewable tablet	Improves patient acceptance and OTC differentiation	Moderate if supported by defined coating or sensory data
Orally disintegrating tablet	Supports patients who cannot swallow tablets	Moderate, but crowded technology area
Pediatric suspension	Enables weight-based dosing and swallowing flexibility	Moderate if stability and dosing performance are distinctive
Famotidine-antacid combination	Combines immediate neutralization with longer acid suppression	Moderate for composition and release architecture
Effervescent tablet or powder	Rapid dispersion and differentiated user experience	Moderate
Modified-release tablet	May reduce dosing frequency	Technically more difficult and clinically constrained
Injectable presentation	Hospital convenience and packaging efficiency	Low to moderate unless stability or container technology is distinctive
Abuse-deterrent or specialty delivery	Limited relevance for famotidine	Low commercial attractiveness

A formulation patent should avoid relying only on ingredient presence. Stronger claims define functional results, such as:

• Dissolution within a specified time window
• Palatability score below a defined bitterness threshold
• Stability after storage at accelerated conditions
• Suspension redispersibility after a defined standing period
• Reduced degradation products
• Improved content uniformity
• Reduced tablet friability at lower compression force

How should companies design a famotidine excipient strategy?

A practical strategy should begin with the target market rather than the active ingredient.

OTC heartburn tablets

The lowest-cost product is a conventional immediate-release tablet. The formulation should prioritize:

• Direct compression or simplified wet granulation
• Low-cost, globally available excipients
• Short disintegration time
• Stable coating and packaging
• Efficient high-speed manufacturing
• Compatibility with multiple tablet strengths

For this segment, excipient innovation alone rarely supports a premium price. Brand positioning, package size, retailer access, and regulatory status are more important than minor performance improvements.

Chewable and orally disintegrating products

Chewable products create a stronger opportunity because taste and mouthfeel determine repeat purchase. The excipient system should address:

• Bitterness
• Chalkiness
• Residual powder
• Tablet hardness
• Chew time
• Moisture sensitivity
• Flavor persistence
• Sweetener aftertaste

Mannitol is often attractive for chewables because of its cooling sensation and relatively clean mouthfeel. Sorbitol, xylitol, sucralose, aspartame, acesulfame potassium, and flavor systems may be used depending on target population and labeling constraints. Polyols can create hygroscopicity and gastrointestinal tolerance issues, so packaging and dose design are important.

Famotidine-antacid combinations

Combination products are among the strongest commercial opportunities. Pepcid Complete combines famotidine with calcium carbonate and magnesium hydroxide, pairing rapid acid neutralization with H2-receptor blockade.[4]

The formulation challenge is balancing:

• Chemical compatibility
• Tablet size
• Antacid loading
• Famotidine dissolution
• Chewability
• Calcium and magnesium taste
• Moisture control
• Dose uniformity
• Separate or coordinated release

A company may seek differentiation through smaller tablets, faster disintegration, improved taste masking, alternative antacid ratios, or a dual-layer architecture. Combination products also require careful regulatory classification and labeling because each active ingredient contributes a different therapeutic effect.

Pediatric oral liquids

Pediatric formulations offer a high-value niche because many generic famotidine products are tablets or injections. Commercial requirements include:

• Accurate weight-based dosing
• Low alcohol content or alcohol-free composition
• Acceptable taste
• Easy redispersion
• Low sedimentation
• Appropriate preservative strategy
• Child-resistant packaging
• Oral-syringe compatibility

A ready-to-use suspension may command a higher price than a conventional tablet, but the business case depends on pediatric demand, pharmacy stocking, stability period, and reimbursement. A powder-for-reconstitution product can reduce shipping and chemical stability burdens but adds preparation risk.

What FDA regulatory issues affect famotidine excipient development?

FDA pathway selection depends on whether the product is a conventional generic, a new combination, a new dosage form, or a product with clinical differentiation.

Product concept	Likely regulatory pathway
Conventional famotidine tablet equivalent	ANDA, subject to bioequivalence and quality requirements
New strength or dosage form based on a listed product	Potential ANDA if permitted by reference-product framework
Famotidine with new antacid combination	NDA, 505(b)(2), or other applicable pathway
New pediatric suspension	ANDA or 505(b)(2), depending on reference and formulation differences
Novel modified-release product	Often 505(b)(2) or full NDA requirements
OTC monograph-compliant product	OTC pathway if formulation, labeling, strength, and conditions satisfy the applicable framework

Excipients must be acceptable for the route, dose, population, and dosage form. A novel excipient may increase regulatory burden, require additional toxicology, and undermine the low-cost generic value proposition. Established excipients with documented oral use are generally preferable unless a new excipient provides a material technical advantage.

FDA's Inactive Ingredient Database can help assess prior use by route and dosage form, but prior listing does not eliminate the need to demonstrate product quality, safety, and performance.[5]

How strong is the famotidine patent estate?

The patent estate is weak for basic famotidine tablets and stronger only for differentiated delivery systems or combinations.

Patent category	Relative strength	Commercial assessment
Famotidine compound patent	Very low	Expired
Conventional immediate-release tablet	Very low	Commodity market
Standard excipient mixture	Low	Vulnerable to obviousness attacks
Taste-masked particles	Moderate	Requires sensory and dissolution evidence
Pediatric suspension	Moderate	Stability and dosing claims may be valuable
Famotidine-antacid combination	Moderate	Composition and release claims may support differentiation
Manufacturing process	Moderate	Can protect cost or impurity-control advantages
Packaging and moisture protection	Low to moderate	Useful commercially, narrower legal scope
Modified-release system	Moderate to high in theory	Clinical and regulatory complexity limits value

Manufacturing know-how may be more valuable than patents. Process controls for particle size, granulation endpoint, lubrication time, coating uniformity, moisture exposure, and impurity management can reduce cost and improve batch consistency. These controls can be protected as trade secrets if they are not readily reverse-engineered.

Which companies are competing in famotidine?

Competition exists across three market tiers:

1. Branded OTC products, led by Pepcid.
2. Retail generic tablets, chewables, and liquids.
3. Hospital injectable products and institutional presentations.

The principal competitive advantages are manufacturing scale, retailer distribution, product availability, package economics, and differentiated dosage forms. The molecule itself provides little basis for premium pricing.

A new entrant is more likely to succeed with one of the following positions:

• A pleasant-tasting chewable for frequent OTC use
• A smaller combination tablet
• A pediatric-ready suspension with long stability
• A pharmacy-friendly unit-dose liquid
• A hospital injection with simplified preparation
• A low-cost product using continuous manufacturing or high-throughput compression
• A product optimized for e-commerce and direct-to-consumer channels

What licensing opportunities exist for famotidine excipients?

Licensing opportunities are more likely to involve enabling technology than famotidine itself. Relevant assets include:

• Taste-masking platforms
• Coated-particle technology
• Pediatric suspension systems
• Direct-compression excipient blends
• Effervescent delivery systems
• Modified-release polymers
• Moisture-barrier packaging
• Oral-syringe and unit-dose presentation systems

A licensee should assess whether the technology is specific enough to create claim differentiation and whether it increases cost beyond the product's expected price premium. A proprietary excipient is unattractive for a commodity tablet unless it materially improves yield, stability, or patient acceptance.

Settlement agreements are not a central feature of the mature famotidine market. Any current dispute involving a new combination or dosage form would need to be evaluated through the specific patent family, product approval, and court docket. The historic expiry of the basic famotidine patent does not eliminate litigation risk for later formulation products.

What revenue exposure exists for branded and generic famotidine?

Famotidine revenue is divided between high-volume, low-price generic products and branded OTC products with stronger margins. Generic tablets face intense price competition and limited switching costs. Branded OTC products can preserve pricing through consumer recognition, packaging, retail placement, and combination products.

Revenue exposure to excipient strategy is highest in:

• Chewable products
• Combination products
• Pediatric liquids
• Convenience-oriented OTC packages
• Hospital formulations that reduce preparation time

Revenue exposure is lowest in an undifferentiated 20 mg or 40 mg immediate-release tablet. A new excipient system must either reduce cost, create a meaningful user benefit, or support a regulatory distinction. Minor changes in filler or lubricant composition are unlikely to alter market share.

How does famotidine compare with competing acid-reducing drugs?

Product class	Example	Excipient opportunity	Competitive issue
H2 antagonist	Famotidine	Chewable, liquid, combination, rapid-dissolution	Mature generic competition
Proton-pump inhibitor	Omeprazole, esomeprazole	Enteric coating, delayed release, stability	Strong OTC and generic competition
Antacid	Calcium carbonate, magnesium hydroxide	Chewability, suspension, fast neutralization	Very low-cost products
Alginate product	Alginate combinations	Raft formation and suspension design	Differentiated physical mechanism
Combination acid reducer	Famotidine plus antacids	Multi-active release and taste masking	Larger tablet and compatibility burden

Famotidine has an advantage in formulation simplicity compared with proton-pump inhibitors because it does not require enteric protection for basic immediate-release delivery. It has a disadvantage against antacids on price and against proton-pump inhibitors in perceived duration and market familiarity.

What generic launch risks exist for a new famotidine product?

A generic or reformulated famotidine launch faces five principal risks:

• Price erosion from established suppliers
• Difficulty obtaining premium pricing for minor excipient changes
• Inadequate taste or mouthfeel in chewable products
• Failure to demonstrate stability or dissolution after scale-up
• Regulatory uncertainty for combinations or novel delivery systems

The most credible launch plan is usually a staged portfolio: a low-cost conventional tablet for baseline volume, followed by a differentiated chewable, suspension, or combination product. This approach uses the same active-ingredient supply chain while allocating development investment to higher-margin dosage forms.

What geographic opportunities exist for famotidine?

The United States offers the largest opportunity for branded OTC differentiation but has high retail competition and demanding packaging and labeling requirements. Europe, Japan, and other developed markets may offer opportunities in prescription, pharmacy, or OTC channels, but regulatory status and local treatment guidelines vary.

Emerging markets may favor:

• Stable tablets with low manufacturing cost
• Small package sizes
• Heat- and humidity-resistant packaging
• Pediatric liquids where refrigeration is limited
• Simple reconstitution systems
• Locally sourced excipients

Geographic expansion requires review of national famotidine approvals, OTC status, permissible excipients, local pharmacopeial standards, and trademark availability. A formulation patent may have value in selected jurisdictions even where the U.S. product is commoditized.

Key Takeaways

• Famotidine's basic compound and conventional tablet protection have expired.
• The commercial opportunity is concentrated in dosage-form differentiation, not active-ingredient exclusivity.
• Chewable tablets, combination products, pediatric suspensions, and rapid-dissolution systems offer the clearest excipient-led opportunities.
• Taste masking, suspension stability, dissolution control, and moisture protection are the main technical priorities.
• Conventional excipient substitutions have weak patent value unless tied to measurable performance benefits.
• Combination products may support stronger commercial differentiation but require more complex regulatory and compatibility work.
• Manufacturing know-how can be more valuable than a narrow formulation patent in a low-price generic market.
• The strongest business case combines a low-cost base product with a premium differentiated presentation.

FAQs

Can famotidine be formulated as an orally disintegrating tablet?

Yes. An orally disintegrating famotidine product can use superdisintegrants, porous carriers, taste-masked particles, and sweetener-flavor systems. The principal development risks are bitterness, tablet friability, moisture sensitivity, and rapid dissolution after oral disintegration.

Is famotidine compatible with calcium carbonate and magnesium hydroxide?

Commercial products demonstrate that famotidine can be combined with calcium carbonate and magnesium hydroxide in an OTC chewable format. Development must control antacid loading, taste, moisture, dissolution, assay uniformity, and tablet size.[4]

What is the most commercially attractive famotidine dosage form?

A pleasant-tasting chewable or a famotidine-antacid combination generally offers more differentiation than a standard tablet. A ready-to-use pediatric suspension may offer a narrower but higher-value market.

Can a new famotidine excipient blend receive patent protection?

Yes, but patent strength depends on technical evidence. Claims based only on replacing one conventional filler with another are vulnerable. Claims supported by improved taste, dissolution, stability, redispersibility, or manufacturing performance are more defensible.

Is famotidine suitable for a modified-release product?

It may be technically feasible, but the commercial case is uncertain. Modified release would require formulation optimization and may require additional clinical or regulatory support. The cost and development burden may exceed the value available in a mature H2-antagonist market.

References

1. U.S. Food and Drug Administration. (1986). Pepcid tablets: Approval history and prescribing information.

2. U.S. Food and Drug Administration. (1988). Pepcid injection: Approval history and prescribing information.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book.

4. Kenvue Brands LLC. (2024). Pepcid Complete chewable tablets: Drug facts and inactive ingredients.

5. U.S. Food and Drug Administration. (2024). Inactive Ingredient Database.